(19)
(11) EP 2 175 884 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.02.2017 Bulletin 2017/08

(45) Mention of the grant of the patent:
15.06.2016 Bulletin 2016/24

(21) Application number: 08780115.5

(22) Date of filing: 11.07.2008
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
(86) International application number:
PCT/US2008/008502
(87) International publication number:
WO 2009/009116 (15.01.2009 Gazette 2009/03)

(54)

COMBINATION THERAPIES EMPLOYING GITR BINDING MOLECULES

KOMBINATIONSTHERAPIEN MIT GITR-BINDENDEN MOLEKÜLEN

THÉRAPIES COMBINÉES UTILISANT DES MOLÉCULES DE LIAISON AU GITR

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 12.07.2007 US 959246 P
30.10.2007 US 1021 P
05.05.2008 US 126431 P

(43) Date of publication of application:
21.04.2010 Bulletin 2010/16

(60) Divisional application:
16170401.0 / 3124046

(73) Proprietor: GITR, Inc.
Cambridge, MA 02142 (US)

(72) Inventors:
  • ROSENZWEIG, Michael
    Boston, MA 02116 (US)
  • PONATH, Paul
    San Francisco, CA 94114 (US)
  • PONTE, Jose, F.
    Quincy, MA 02169 (US)

(74) Representative: Nash, David Allan 
Haseltine Lake LLP Redcliff Quay 120 Redcliff Street
Bristol BS1 6HU
Bristol BS1 6HU (GB)


(56) References cited: : 
WO-A1-03/006058
WO-A2-2006/105021
US-A1- 2005 238 628
US-A1- 2007 098 719
 WO-A2-2004/107618
US-A1- 2004 157 786
US-A1- 2006 134 102
   
  • A. D. COHEN ET AL: "Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity", CANCER RESEARCH, vol. 66, no. 9, 1 May 2006 (2006-05-01), pages 4904-4912, XP055049643, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-2813
  • COHEN ADAM D ET AL: "An agonist anti-GITR antibodyenhances effector and memory CD8 T cell responses and tumor immunity following xenogeneic DNA immunization against melanoma.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04), page 624, XP9166231, & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005 ISSN: 0197-016X
  • GAFFNEY MARY C ET AL: "DNA vaccination targeting mesothelin combined with anti-GITR antibody induces rejection of pancreatic adenocarcinoma.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 47, April 2006 (2006-04), page 329, XP9166228, & 97TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); WASHINGTON, DC, USA; APRIL 01 -05, 2006 ISSN: 0197-016X
  • KO K ET AL: "TREATMENT OF ADVANCED TUMORS WITH AGONISTIC ANTI-GITR MAB AND ITS EFFECTS ON TUMOR-INFILTRATING FOXP3(+)CD25(+)CD4(+) REGULATORY T CELLS", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 202, no. 7, 3 October 2005 (2005-10-03), pages 885-891, XP009076415, ISSN: 0022-1007, DOI: 10.1084/JEM.20050940
  • TURK MARY JO ET AL: "Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 200, no. 6, 20 September 2004 (2004-09-20), pages 771-782, XP009148395, ISSN: 0022-1007, DOI: 10.1084/JEM.20041130
  • TERESA RAMIREZ MONTAGUT ET AL: "Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.", THE JOURNAL OF IMMUNOLOGY, vol. 176, no. 11, 1 June 2006 (2006-06-01) , pages 6434-6442, XP055049701, ISSN: 0022-1767
  • ABRAHAM J ET AL: "Pharmacogenetics of cancer chemotherapy", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1766, no. 2, 1 December 2006 (2006-12-01), pages 168-183, XP024963996, ISSN: 0304-419X, DOI: 10.1016/J.BBCAN.2006.10.003 [retrieved on 2006-12-01]
  • H.-J. KO ET AL: "A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model", CANCER RESEARCH, vol. 67, no. 15, 1 August 2007 (2007-08-01), pages 7477-7486, XP055049594, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-4639
  • ROSENBERG ET AL.: 'A New Approach to the Adoptive Immunotherapy of Cancer with Tumor- Infiltrating Lymphocytes.' SCIENCE vol. 233, no. 4770, September 1986, pages 1318 - 1321, XP000196187
  • MOKYR M B ET AL: "Realization of the therapeutic potential of CTLA - 4 blockade in low-dose chemotherapy-treated tumor -bearing mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 58, no. 23, 1 December 1998 (1998-12-01), pages 5301-5304, XP002213882, ISSN: 0008-5472
  • "Combining cancer vaccines with chemotherapy", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 6, no. 16, 1 January 2005 (2005-01-01), pages 2813-2820, XP008142780, ISSN: 1465-6566
  • ANNA K NOWAK ET AL: "Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 63, no. 15, 1 August 2003 (2003-08-01), pages 4490-4496, XP008156419, ISSN: 0008-5472 [retrieved on 2003-08-07]
  • Bonnee Rubinfeld ET AL: "Identification and immunotherapeutic targeting of antigens induced by chemotherapy", Nature Biotechnology, vol. 24, no. 2, 29 January 2006 (2006-01-29), pages 205-209, XP055084268, ISSN: 1087-0156, DOI: 10.1038/nbt1185
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).